APOE ε4 carriers were younger at study entry (χ2 = 59.97, P = 4.43 × 10−14), were more likely to have cognitive impairment at baseline (χ2 = 138.32, P < 2.2 × 10−16), and were more likely to be longitudinal diagnosis converters (χ2 = 92.34, P < 2.2 × 10−16) compared to APOE ε4 non‐carriers. The gene discussed is APOE; the disease is Cognitive impairment.